BR112022002630A2 - Composição farmacêutica em pó seco adequada para administração por inalação, inalador de pó seco e método de tratamento ou prevenção de doenças ou condições - Google Patents
Composição farmacêutica em pó seco adequada para administração por inalação, inalador de pó seco e método de tratamento ou prevenção de doenças ou condiçõesInfo
- Publication number
- BR112022002630A2 BR112022002630A2 BR112022002630A BR112022002630A BR112022002630A2 BR 112022002630 A2 BR112022002630 A2 BR 112022002630A2 BR 112022002630 A BR112022002630 A BR 112022002630A BR 112022002630 A BR112022002630 A BR 112022002630A BR 112022002630 A2 BR112022002630 A2 BR 112022002630A2
- Authority
- BR
- Brazil
- Prior art keywords
- dry powder
- pharmaceutical composition
- inhalation
- administration
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1911517.9A GB201911517D0 (en) | 2019-08-12 | 2019-08-12 | Pharmaceutical composition |
| PCT/GB2020/051914 WO2021028679A1 (en) | 2019-08-12 | 2020-08-12 | Pharmaeutical composition comprising ensifentrine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022002630A2 true BR112022002630A2 (pt) | 2022-05-03 |
Family
ID=67991071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022002630A BR112022002630A2 (pt) | 2019-08-12 | 2020-08-12 | Composição farmacêutica em pó seco adequada para administração por inalação, inalador de pó seco e método de tratamento ou prevenção de doenças ou condições |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220265549A1 (https=) |
| EP (1) | EP4013384A1 (https=) |
| JP (1) | JP7678793B2 (https=) |
| KR (1) | KR20220045214A (https=) |
| CN (1) | CN114286672A (https=) |
| AU (1) | AU2020328223B2 (https=) |
| BR (1) | BR112022002630A2 (https=) |
| CA (1) | CA3144713A1 (https=) |
| GB (1) | GB201911517D0 (https=) |
| IL (2) | IL326396A (https=) |
| MX (1) | MX2022001724A (https=) |
| MY (1) | MY208922A (https=) |
| PH (1) | PH12022550322A1 (https=) |
| WO (1) | WO2021028679A1 (https=) |
| ZA (1) | ZA202201322B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7307855B2 (ja) * | 2019-10-11 | 2023-07-12 | テレフオンアクチーボラゲット エルエム エリクソン（パブル） | 無線通信ネットワークにおける設定ダウンリンク送信および動的ダウンリンク送信をハンドリングする方法および装置 |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| CN120787157A (zh) * | 2022-10-20 | 2025-10-14 | 维罗纳制药公司 | 使用恩塞芬汀治疗特发性肺纤维化 |
| KR20250087621A (ko) * | 2022-10-28 | 2025-06-16 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 이소퀴놀리논계 화합물을 포함하는 약학적 조성물 및 이의 제조 방법 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| WO2025003643A1 (en) * | 2023-06-26 | 2025-01-02 | Verona Pharma Plc | Particulate composition comprising ensifetrine |
| AU2024309346C1 (en) | 2023-06-26 | 2026-03-12 | Verona Pharma Plc | Particulate composition comprising ensifentrine |
| WO2025052119A1 (en) * | 2023-09-06 | 2025-03-13 | Verona Pharma Plc | Ensifentrine for use in treating chronic obstructive pulmonary disease (copd) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4140689B4 (de) * | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalationspulver und Verfahren zu ihrer Herstellung |
| DE60005493T2 (de) | 1999-03-31 | 2004-07-01 | Vernalis Ltd., Wokingham | Pyrimido[6,1-a]isochinolinonderivate |
| JO3102B1 (ar) | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
| EP2968312B1 (en) * | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
| PL3231444T3 (pl) | 2014-05-12 | 2020-05-18 | Verona Pharma Plc | Nowe leczenie |
| MY196072A (en) | 2014-09-15 | 2023-03-13 | Verona Pharma Plc | Liquid Inhalation Formulation Comprising RPL554 |
| GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
-
2019
- 2019-08-12 GB GBGB1911517.9A patent/GB201911517D0/en not_active Ceased
-
2020
- 2020-08-12 PH PH1/2022/550322A patent/PH12022550322A1/en unknown
- 2020-08-12 MY MYPI2022000719A patent/MY208922A/en unknown
- 2020-08-12 WO PCT/GB2020/051914 patent/WO2021028679A1/en not_active Ceased
- 2020-08-12 BR BR112022002630A patent/BR112022002630A2/pt unknown
- 2020-08-12 JP JP2022508963A patent/JP7678793B2/ja active Active
- 2020-08-12 CN CN202080056792.8A patent/CN114286672A/zh active Pending
- 2020-08-12 EP EP20758285.9A patent/EP4013384A1/en active Pending
- 2020-08-12 AU AU2020328223A patent/AU2020328223B2/en active Active
- 2020-08-12 CA CA3144713A patent/CA3144713A1/en active Pending
- 2020-08-12 KR KR1020227008300A patent/KR20220045214A/ko active Pending
- 2020-08-12 IL IL326396A patent/IL326396A/en unknown
- 2020-08-12 MX MX2022001724A patent/MX2022001724A/es unknown
- 2020-08-12 US US17/632,891 patent/US20220265549A1/en active Pending
-
2022
- 2022-01-27 ZA ZA2022/01322A patent/ZA202201322B/en unknown
- 2022-02-08 IL IL290447A patent/IL290447B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220045214A (ko) | 2022-04-12 |
| ZA202201322B (en) | 2024-06-26 |
| IL290447A (en) | 2022-04-01 |
| CN114286672A (zh) | 2022-04-05 |
| WO2021028679A1 (en) | 2021-02-18 |
| GB201911517D0 (en) | 2019-09-25 |
| WO2021028679A8 (en) | 2022-02-24 |
| CA3144713A1 (en) | 2021-02-18 |
| AU2020328223B2 (en) | 2025-09-04 |
| JP2022550664A (ja) | 2022-12-05 |
| US20220265549A1 (en) | 2022-08-25 |
| JP7678793B2 (ja) | 2025-05-16 |
| IL290447B1 (en) | 2026-03-01 |
| IL326396A (en) | 2026-04-01 |
| PH12022550322A1 (en) | 2023-02-13 |
| MY208922A (en) | 2025-06-11 |
| MX2022001724A (es) | 2022-03-11 |
| EP4013384A1 (en) | 2022-06-22 |
| AU2020328223A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022002630A2 (pt) | Composição farmacêutica em pó seco adequada para administração por inalação, inalador de pó seco e método de tratamento ou prevenção de doenças ou condições | |
| BR112023000300A2 (pt) | Composições à base de aloe vera compreendendo polisacarídeos e polifenóis para regulação de homeostase de imunidade | |
| BR112022001413A2 (pt) | Preparação de canabidiol, e, método para tratar uma modificação da doença em um paciente que sofre de síndrome de dravet | |
| BR112021022139A2 (pt) | Preparação de canabidiol, e, método para tratar um paciente que sofre de espasmos epilépticos | |
| BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
| JP7778685B2 (ja) | ピラジン誘導体と他のコロナウイルス感染症治療薬とを組み合わせてなるコロナウイルス感染症治療剤 | |
| BR112017004048A2 (pt) | formulações de pó inalável de oligômeros de alginato | |
| Nguyen et al. | Sigma receptors as potential therapeutic targets for neuroprotection | |
| BR112016013734A2 (pt) | Composto, composição farmacêutica, kit, e uso de um composto | |
| MX391339B (es) | Composicion farmaceutica que comprende selexipag. | |
| BR112012022552A8 (pt) | uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos | |
| BR112021021775A2 (pt) | Composições de pó seco de pró-fármacos de treprostinil e métodos de uso destas | |
| BR112015011213A2 (pt) | Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição. | |
| BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
| BR112022025449A2 (pt) | Composição imunológica útil para induzir a produção de anticorpos para um antígeno em um animal não humano, e, uso da mesma | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112012016570A2 (pt) | composto, composição farmacêutica, método para antagonizar a heparina não fracionada, heparina de peso molecular baixo, ou derivado de heparina /heparina de peso molecular baixo, e, uso do composto | |
| BR112021021029A2 (pt) | Preparação de canabidiol, e, método para tratar um paciente que sofre de crises associadas ao complexo de esclerose tuberosa | |
| MX375427B (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion | |
| BR112015009486A2 (pt) | surfactante reconstituído, formulação farmacêutica, kit e uso de surfactante reconstituído | |
| BR112018068784A2 (pt) | método para o tratamento de leucemia | |
| Behera et al. | Allyl sulfide promotes osteoblast differentiation and bone density via reducing mitochondrial DNA release mediated Kdm6b/H3K27me3 epigenetic mechanism | |
| Arnaoutoglou et al. | The effects of propofol or sevoflurane on free radical production after tourniquet induced ischaemia-reperfusion, injury during knee arthroplasty | |
| BR112022001395A2 (pt) | Métodos para administrar anticorpos anti-siglec-8 e corticosteroides | |
| MX373699B (es) | Composicion farmaceutica que contiene budesonida y formoterol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |